why choose us

First received: February 06, 2023

Clinical Trial: A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidomide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed Refractory Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients

Brief Summary: The study is researching an experimental drug called linvoseltamab, also called REGN5458.Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed.These participants were no longer benefiting from standard medications and had no good treatment options.In that study, some participants who were treated with linvoseltamab had improvement of their myeloma…

Read more